氟脲嘧啶脱氧核苷联合顺铂诱导化疗治疗局部晚期鼻咽癌的临床研究  

The clinical study of FUDR plus cisplatin for treatment of locally advanced nasopharyngeal carcinoma

作　　者：曾子君[1] 林映如[1] 

机构地区：[1]广东省人民医院肿瘤中心放疗科,广州510080

出　　处：《重庆医学》2008年第18期2071-2072,共2页Chongqing medicine

摘　　要：目的比较氟脲嘧啶脱氧核苷（FUDR）或5氟脲嘧啶（5-Fu）联合顺铂（DDP）两种诱导化疗方案治疗局部晚期鼻咽癌的近期疗效和不良反应。方法40例Ⅲ期、Ⅳa中晚期鼻咽癌患者随机分为实验组（采用DDP＋FUDR方案）和对照组（采用DDP＋5-Fu方案），每纽20例。实验组方案为：DDP 20mg·m^-2·d^-1，静脉滴注，第1～5天，FUDR 500mg·m^-2·d^-1静脉滴注，第1～5天；21d为1个疗程。对照组化疗方案：5-Fu代替FuDR，其余剂量、用法与实验组相同。两组连用2个疗程后休息10～14d开始放疗。鼻咽原发灶剂量DT：70～76Gy／7～8w，颈部转移灶DT：60～70Gy／6～7w。结果实验组和对照组的化疗结束时有效率分别为80％和75％（P〉0．05），放疗结束时有效率lOO％。实验组的口腔黏膜炎严重程度明显比对照组轻（P〈0．01）。结论DDP＋FUDR是中晚期鼻咽癌诱导化疗的有效方案，不良反应较少。Objective To compare the therapeutic effect and adverse reaction of FUDR plus cisplatin with 5-Fu plus cisplatin followed by radiotherapy for treatment of locally advanced nasopharyngeal carcinoma. Methods 40 cases of locally advanced naso pharyngeal carcinoma were randomly divided into two groups, trial group（DDP4-FUDR） and control group （DDP＋5-Fu）, every group included 20 patients, the trial group was DDP（20mg·m^-2·d^-1 , 1 -- 5d, ivdrip） plus FUDR（500mg·m^-2·d^-1 , 1 -- 5d, ivdrip）, every 21 days as one course of treatment, while the control group was only FUDR changed 5-Fu, the dosage and usage were the same as the trial group. Radiotherapy followed two cycles of chemotherapy 10--14 days later. The radiotherapy was given at dose of 70--76Gy/7--8W to nasopharynx,and dose of to 60--70Gy/6--7W to neck. Results The response rates of the trial group and the control group were 80 % and 75% （P〉0. 05） respectively, when the two cycles of chemotherapy were finished. And the response rates of both of two groups were 100 % when the radiotherapy was finished. However, during the treatment, patients with severe acute oral mucositis in the trial group were less than that in the control group（P〈0.01）. Conclusion DDP＋FUDR can be used as neo adjuvant chemotherapy for treatment of locally advanced nasopharyngeal carcinoma,the side effect is less.

关 键 词：鼻咽癌 氟脲嘧啶脱氧核苷 诱导化疗 

分 类 号：R739.63[医药卫生—肿瘤] R730.53[医药卫生—临床医学]